1. Home
  2. ZURA vs ELUT Comparison

ZURA vs ELUT Comparison

Compare ZURA & ELUT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ZURA
  • ELUT
  • Stock Information
  • Founded
  • ZURA 2022
  • ELUT 2015
  • Country
  • ZURA United States
  • ELUT United States
  • Employees
  • ZURA N/A
  • ELUT N/A
  • Industry
  • ZURA Biotechnology: Biological Products (No Diagnostic Substances)
  • ELUT Medical Specialities
  • Sector
  • ZURA Health Care
  • ELUT Health Care
  • Exchange
  • ZURA Nasdaq
  • ELUT Nasdaq
  • Market Cap
  • ZURA 69.9M
  • ELUT 71.5M
  • IPO Year
  • ZURA N/A
  • ELUT 2020
  • Fundamental
  • Price
  • ZURA $1.31
  • ELUT $2.38
  • Analyst Decision
  • ZURA Buy
  • ELUT Strong Buy
  • Analyst Count
  • ZURA 7
  • ELUT 2
  • Target Price
  • ZURA $14.33
  • ELUT $8.00
  • AVG Volume (30 Days)
  • ZURA 708.2K
  • ELUT 26.4K
  • Earning Date
  • ZURA 08-08-2025
  • ELUT 08-06-2025
  • Dividend Yield
  • ZURA N/A
  • ELUT N/A
  • EPS Growth
  • ZURA N/A
  • ELUT N/A
  • EPS
  • ZURA N/A
  • ELUT N/A
  • Revenue
  • ZURA N/A
  • ELUT $23,711,000.00
  • Revenue This Year
  • ZURA N/A
  • ELUT $20.10
  • Revenue Next Year
  • ZURA N/A
  • ELUT $85.89
  • P/E Ratio
  • ZURA N/A
  • ELUT N/A
  • Revenue Growth
  • ZURA N/A
  • ELUT N/A
  • 52 Week Low
  • ZURA $0.97
  • ELUT $1.61
  • 52 Week High
  • ZURA $5.07
  • ELUT $5.12
  • Technical
  • Relative Strength Index (RSI)
  • ZURA 59.63
  • ELUT 69.40
  • Support Level
  • ZURA $1.00
  • ELUT $2.08
  • Resistance Level
  • ZURA $1.45
  • ELUT $2.23
  • Average True Range (ATR)
  • ZURA 0.10
  • ELUT 0.19
  • MACD
  • ZURA 0.03
  • ELUT 0.07
  • Stochastic Oscillator
  • ZURA 68.89
  • ELUT 81.52

About ZURA Zura Bio Limited

Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.

About ELUT Elutia Inc.

Elutia Inc Formerly Aziyo Biologics Inc is a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, concentrating on patients receiving implantable medical devices. The company's segments include Device Protection, Women's Health and Cardiovascular. It generates maximum revenue from the Women's Health segment. The products of the company are targeted to address unmet clinical needs with the goal of promoting healthy tissue formation and avoiding complications associated with medical device implants, such as scar-tissue formation, capsular contraction, erosion, migration, non-union of implants and implant rejection.

Share on Social Networks: